Cereblon Ligand-Linker Conjugates 9 are primarily utilized in the field of targeted protein degradation, particularly in the development of Proteolysis-Targeting Chimeras (PROTACs). These conjugates play a crucial role in designing molecules that can selectively degrade disease-causing proteins, offering a novel approach in drug discovery. By binding to the cereblon protein, they facilitate the recruitment of specific target proteins to the ubiquitin-proteasome system, leading to their degradation. This mechanism is especially promising in cancer therapy, where it can be used to degrade oncogenic proteins that are otherwise difficult to target with traditional small-molecule inhibitors. Additionally, these conjugates are being explored in the treatment of neurodegenerative diseases and other conditions driven by aberrant protein accumulation. Their ability to induce targeted protein degradation opens new avenues for therapeutic interventions, potentially overcoming limitations associated with conventional drug modalities.